Literature DB >> 19587305

Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug.

Alexandre P Zavascki, Jian Li, Roger L Nation, Silvana V Superti, Afonso L Barth, Larissa Lutz, Fabiano Ramos, Márcio M Boniatti, Luciano Z Goldani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19587305      PMCID： PMC2738066          DOI： 10.1128/JCM.01035-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  8 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

Review 2.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.

Authors:  Alexandre Prehn Zavascki; Luciano Zubaran Goldani; Jian Li; Roger L Nation
Journal:  J Antimicrob Chemother       Date:  2007-09-17       Impact factor: 5.790

3.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Jooyun Lee; Gopi Patel; Shirish Huprikar; David P Calfee; Stephen G Jenkins
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948

5.  Intravenous colistimethate for multidrug-resistant Gram-negative bacteria.

Authors:  Alexandre P Zavascki; Jian Li
Journal:  Lancet Infect Dis       Date:  2008-07       Impact factor: 25.071

6.  Pharmacokinetics of intravenous polymyxin B in critically ill patients.

Authors:  Alexandre P Zavascki; Luciano Z Goldani; Guoying Cao; Silvana V Superti; Larissa Lutz; Afonso L Barth; Fabiano Ramos; Márcio M Boniatti; Roger L Nation; Jian Li
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

7.  In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.

Authors:  Anima Poudyal; Benjamin P Howden; Jan M Bell; Wei Gao; Roxanne J Owen; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2008-10-15       Impact factor: 5.790

8.  Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation; John D Turnidge; Kingsley Coulthard; Robert W Milne
Journal:  J Antimicrob Chemother       Date:  2008-01-28       Impact factor: 5.790
  8 in total
  3 in total

1.  Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii.

Authors:  M H Rigatto; V B Ribeiro; D Konzen; A P Zavascki
Journal:  Infection       Date:  2012-11-04       Impact factor: 3.553

2.  Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.

Authors:  Pooja Manchandani; Jian Zhou; Kimberly R Ledesma; Luan D Truong; Diana S-L Chow; Jason L Eriksen; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

3.  Activities of tobramycin and polymyxin E against Pseudomonas aeruginosa biofilm-coated medical grade endotracheal tubes.

Authors:  Keiko Tarquinio; Kelsey Confreda; James Shurko; Kerry LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.